Momenta Pharmaceuticals Inc. (MNTA)

11.39
0.21 1.88
NASDAQ : Health Technology
Prev Close 11.18
Open 11.14
Day Low/High 10.96 / 11.50
52 Wk Low/High 10.10 / 32.20
Volume 467.50K
Avg Volume 823.80K
Exchange NASDAQ
Shares Outstanding 96.00M
Market Cap 1.15B
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting MNTA Put And Call Options For August 17th

Interesting MNTA Put And Call Options For August 17th

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAXN, GBLI, HAE, NWN, OXY, QDEL, TTI, ZBRA Downgrades: AC, ACM, ARMK, COKE, EDN, EPR, IT, KEYW, MG, MNTA, TEN, TRIP Initiations: DSKE, SNAP Read on to get TheStreet Quant Ratings' detailed report:

MNTA Crosses Above Average Analyst Target

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $17.50, changing hands for $17.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Short Interest In Momenta Pharmaceuticals Drops 12.6%

Short Interest In Momenta Pharmaceuticals Drops 12.6%

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 655,715 share decrease in total short interest for Momenta Pharmaceuticals Inc , to 4,539,415, a decrease of 12.62% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week Of MNTA April 20th Options Trading

First Week Of MNTA April 20th Options Trading

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new April 20th contracts and identified one put and one call contract of particular interest.

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.

MNTA Crosses Above Average Analyst Target

MNTA Crosses Above Average Analyst Target

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $15.75/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Momenta Pharmaceuticals, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Momenta Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc.

The Stock Market Is on Autopilot

The Stock Market Is on Autopilot

This market is badly in need of some resets as it has been nearly straight up the first week of the year.

Momenta And Mylan Announce Development Strategy For M710, A Proposed Biosimilar To EYLEA® (aflibercept)

Momenta And Mylan Announce Development Strategy For M710, A Proposed Biosimilar To EYLEA® (aflibercept)

Targeting the initiation of a pivotal patient clinical trial in the first half of 2018

MNTA Crosses Above Average Analyst Target

MNTA Crosses Above Average Analyst Target

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $14.00, changing hands for $14.10/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

First Week of January 2018 Options Trading For Momenta Pharmaceuticals (MNTA)

First Week of January 2018 Options Trading For Momenta Pharmaceuticals (MNTA)

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

Momenta Pharmaceuticals Stock Sees Short Interest Move 10.3% Higher

Momenta Pharmaceuticals Stock Sees Short Interest Move 10.3% Higher

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 699,664 share increase in total short interest for Momenta Pharmaceuticals Inc , to 7,483,025, an increase of 10.31% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers

The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.

First Week Of MNTA June 2018 Options Trading

First Week Of MNTA June 2018 Options Trading

Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D (Sell)